Comparative Analysis of a Complex Monoclonal Antibody

Postnova Analytics has published a new poster that compares the suitability of Electrical Asymmetrical Flow Field Flow Fractionation (EAF4) and Size Exclusion Chromatography (SEC) for determining the physicochemical and biophysical attributes of monoclonal antibodies.

In the described work, a reference monoclonal antibody (RM 8671 mAb), from the U.S. National Institute of Standards and Technology (NIST), was used to compare separation, aggregation quantification, and recovery parameters for an EAF4-UV-MALS versus SEC-UV-MALS techniques. The NIST mAb provides a representative test molecule for development of novel technology for therapeutic protein characterization.

The poster describes how the EAF4 module enabled simultaneous measurement of size and surface charge characteristics (electrophoretic mobility) of antibodies and proteins.

Further while no aggregates were detected by SEC, the FFF system showed protein / antibody aggregates represented 10% of the total mass injected.

 

 

 

The researchers concluded that the FFF open channel design may allow for better recovery of injected mass than SEC which is particularly important when seeking to quantify aggregates present in small amounts.

Postnova Analytics EAF4 technology uniquely combines the principle of Electrical and Asymmetrical Flow FFF in just one system. In an EAF2000 system - Electrical and Cross Flow Fields are applied simultaneously across the FFF channel enabling separations by size and particle charge based on electrophoretic mobility.

Combining these two powerful separation techniques in a single platform opens the door to characterising complex proteins, antibodies and viruses as well as environmental and charged nanoparticles or polymers that have proven intractable to other techniques.

About Postnova Analytics

Founded in 1997, Postnova Analytics is the inventor and leading international supplier of Field-Flow Fractionation (FFF) systems for markets including biopharmaceuticals, polymers, materials, nanotechnology and environmental sciences.

Leveraging its unique and patented modular FFF - Light Scattering Platform, Postnova has been able to provide high performance solutions to a wide range of applications. Today the company's growing product portfolio includes Flow FFF, Centrifugal FFF, Thermal FFF, Size Exclusion Chromatography (SEC), MALS and DLS Light Scattering.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Postnova Analytics. (2018, July 28). Comparative Analysis of a Complex Monoclonal Antibody. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20180523/Comparative-Analysis-of-a-Complex-Monoclonal-Antibody.aspx.

  • MLA

    Postnova Analytics. "Comparative Analysis of a Complex Monoclonal Antibody". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20180523/Comparative-Analysis-of-a-Complex-Monoclonal-Antibody.aspx>.

  • Chicago

    Postnova Analytics. "Comparative Analysis of a Complex Monoclonal Antibody". News-Medical. https://www.news-medical.net/news/20180523/Comparative-Analysis-of-a-Complex-Monoclonal-Antibody.aspx. (accessed November 21, 2024).

  • Harvard

    Postnova Analytics. 2018. Comparative Analysis of a Complex Monoclonal Antibody. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20180523/Comparative-Analysis-of-a-Complex-Monoclonal-Antibody.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.